Cargando…

MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer

Cancer is frequently caused by microRNAs, which control post-transcriptional levels of gene expression by binding to target mRNAs. MiR-29a-3p has recently been shown to play a twofold function in the majority of malignancies, including colorectal cancer (CRC), according to mounting evidence. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Wen-Yan, Cao, Shi-Qiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941256/
https://www.ncbi.nlm.nih.gov/pubmed/36355327
http://dx.doi.org/10.1007/s12094-022-02978-6
_version_ 1784891248600940544
author Mo, Wen-Yan
Cao, Shi-Qiong
author_facet Mo, Wen-Yan
Cao, Shi-Qiong
author_sort Mo, Wen-Yan
collection PubMed
description Cancer is frequently caused by microRNAs, which control post-transcriptional levels of gene expression by binding to target mRNAs. MiR-29a-3p has recently been shown to play a twofold function in the majority of malignancies, including colorectal cancer (CRC), according to mounting evidence. Here, we not only briefly summarize such connection between miR-29a-3p and cancers, but aslo primarily evaluate the miR-29a-3p expression pattern, clinical applicability, and molecular mechanisms in CRC to provide a guide for future studies. This review established the diagnostic and prognostic value of miR-29a-3p abnormalty in a variety of clinical samples for CRC. Furthermore, current molecular mechanisms of miR-29a-3p for regulating cancerous biological processes such growth, invasion, metastasis, the epithelial-mesenchymal transformation process, and immunomodulation through its upstream regulatory factors and downstream targeted genes were briefly explored. More specifically, miR-29a-3p has been linked to a few medications that have been shown to have anticancer benefits. To sum up, miR-29a-3p is a promising biomarker and prospective therapeutic target for the diagnosis and prognosis of CRC, but further research is still needed to establish a theoretical basis for more practical applications.
format Online
Article
Text
id pubmed-9941256
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-99412562023-02-22 MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer Mo, Wen-Yan Cao, Shi-Qiong Clin Transl Oncol Review Article Cancer is frequently caused by microRNAs, which control post-transcriptional levels of gene expression by binding to target mRNAs. MiR-29a-3p has recently been shown to play a twofold function in the majority of malignancies, including colorectal cancer (CRC), according to mounting evidence. Here, we not only briefly summarize such connection between miR-29a-3p and cancers, but aslo primarily evaluate the miR-29a-3p expression pattern, clinical applicability, and molecular mechanisms in CRC to provide a guide for future studies. This review established the diagnostic and prognostic value of miR-29a-3p abnormalty in a variety of clinical samples for CRC. Furthermore, current molecular mechanisms of miR-29a-3p for regulating cancerous biological processes such growth, invasion, metastasis, the epithelial-mesenchymal transformation process, and immunomodulation through its upstream regulatory factors and downstream targeted genes were briefly explored. More specifically, miR-29a-3p has been linked to a few medications that have been shown to have anticancer benefits. To sum up, miR-29a-3p is a promising biomarker and prospective therapeutic target for the diagnosis and prognosis of CRC, but further research is still needed to establish a theoretical basis for more practical applications. Springer International Publishing 2022-11-10 2023 /pmc/articles/PMC9941256/ /pubmed/36355327 http://dx.doi.org/10.1007/s12094-022-02978-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Mo, Wen-Yan
Cao, Shi-Qiong
MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer
title MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer
title_full MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer
title_fullStr MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer
title_full_unstemmed MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer
title_short MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer
title_sort mir-29a-3p: a potential biomarker and therapeutic target in colorectal cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941256/
https://www.ncbi.nlm.nih.gov/pubmed/36355327
http://dx.doi.org/10.1007/s12094-022-02978-6
work_keys_str_mv AT mowenyan mir29a3papotentialbiomarkerandtherapeutictargetincolorectalcancer
AT caoshiqiong mir29a3papotentialbiomarkerandtherapeutictargetincolorectalcancer